GD
IONS icon

Grandfield & Dodd’s Ionis Pharmaceuticals IONS Stock Holding History

Grandfield & Dodd’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.8M Sell
37,326
-495
-1% -$39.1K 0.16% 71
2025
Q4 		$2.99M Buy
37,821
+146
+0.4% +$11K 0.17% 71
2025
Q3 		$2.46M Buy
37,675
+445
+1% +$21.7K 0.14% 79
2025
Q2 		$1.47M Sell
37,230
-531
-1% -$17.4K 0.09% 98
2025
Q1 		$1.14M Buy
37,761
+1,874
+5% +$61.4K 0.07% 103
2024
Q4 		$1.25M Buy
35,887
+1,074
+3% +$40.1K 0.08% 101
2024
Q3 		$1.39M Buy
34,813
+760
+2% +$35.4K 0.08% 97
2024
Q2 		$1.62M Buy
34,053
+279
+0.8% +$11.4K 0.1% 90
2024
Q1 		$1.46M Buy
33,774
+670
+2% +$31.9K 0.09% 94
2023
Q4 		$1.67M Buy
33,104
+242
+0.7% +$11.6K 0.12% 87
2023
Q3 		$1.49M Buy
32,862
+183
+0.6% +$7.55K 0.11% 86
2023
Q2 		$1.34M Buy
32,679
+395
+1% +$15.2K 0.09% 94
2023
Q1 		$1.15M Buy
32,284
+810
+3% +$30.4K 0.08% 98
2022
Q4 		$1.19M Buy
31,474
+2,403
+8% +$101K 0.09% 95
2022
Q3 		$1.29M Buy
29,071
+795
+3% +$33.5K 0.11% 89
2022
Q2 		$1.05M Buy
28,276
+275
+1% +$10.4K 0.08% 97
2022
Q1 		$1.04M Buy
28,001
+1,230
+5% +$40.3K 0.07% 100
2021
Q4 		$810K Buy
26,771
+5,080
+23% +$160K 0.05% 113
2021
Q3 		$730K Buy
21,691
+638
+3% +$24K 0.05% 116
2021
Q2 		$840K Buy
21,053
+700
+3% +$27.4K 0.06% 109
2021
Q1 		$920K Buy
20,353
+711
+4% +$39.7K 0.07% 101
2020
Q4 		$1.11M Buy
19,642
+605
+3% +$30.1K 0.09% 92
2020
Q3 		$900K Buy
19,037
+336
+2% +$18.7K 0.08% 97
2020
Q2 		$1.1M Buy
18,701
+1,365
+8% +$75.9K 0.11% 89
2020
Q1 		$820K Buy
17,336
+660
+4% +$36.8K 0.1% 94
2019
Q4 		$1.01M Buy
16,676
+855
+5% +$50.9K 0.09% 95
2019
Q3 		$948K Buy
15,821
+1,170
+8% +$76.3K 0.09% 92
2019
Q2 		$942K Buy
14,651
+808
+6% +$57.1K 0.09% 95
2019
Q1 		$1.12M Buy
13,843
+99
+0.7% +$6.39K 0.12% 87
2018
Q4 		$743K Buy
13,744
+165
+1% +$8.41K 0.09% 101
2018
Q3 		$700K Buy
13,579
+110
+0.8% +$5.17K 0.07% 110
2018
Q2 		$561K Buy
13,469
+80
+0.6% +$3.55K 0.06% 121
2018
Q1 		$590K Sell
13,389
-280
-2% -$14.2K 0.07% 115
2017
Q4 		$688K Buy
13,669
+290
+2% +$15.9K 0.07% 111
2017
Q3 		$678K Buy
13,379
+570
+4% +$29.9K 0.08% 111
2017
Q2 		$652K Buy
12,809
+690
+6% +$32.1K 0.08% 113
2017
Q1 		$487K Buy
12,119
+135
+1% +$6.06K 0.06% 129
2016
Q4 		$573K Buy
11,984
+1,580
+15% +$62.5K 0.07% 115
2016
Q3 		$381K Sell
10,404
-780
-7% -$24.4K 0.05% 135
2016
Q2 		$260K Buy
11,184
+2,574
+30% +$83K 0.04% 155
2016
Q1 		$349K Buy
8,610
+3,235
+60% +$131K 0.05% 132
2015
Q4 		$333K Buy
+5,375
New +$290K 0.05% 138
2015
Q3 		– Sell
-3,700
Closed -$213K – 173
2015
Q2 		$213K Buy
+3,700
New +$235K 0.03% 166

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Grandfield & Dodd's IONS Position: Q1 2026 in Review

Grandfield & Dodd reduced its Ionis Pharmaceuticals (IONS) stake by 1.3% in Q1 2026, selling an estimated $39.1K and leaving 37,326 shares worth $2.8M. The position accounts for 0.16% of the portfolio, ranked #71.

Grandfield & Dodd first reported a position in IONS in Q2 2015 and has held it in 43 quarters since. The position peaked at $2.99M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Grandfield & Dodd held 37,326 shares of Ionis Pharmaceuticals worth $2.8M as of Q1 2026.
  • Grandfield & Dodd sold 495 Ionis Pharmaceuticals shares in Q1 2026, an estimated $39.1K.
  • Ionis Pharmaceuticals made up 0.16% of Grandfield & Dodd's portfolio in Q1 2026, its #71 holding.
  • Grandfield & Dodd first reported a position in Ionis Pharmaceuticals in Q2 2015 and has held it in 43 quarters since.
  • Grandfield & Dodd's Ionis Pharmaceuticals position peaked at $2.99M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.